Jacquita Jordan
Family · Colorado Springs, CONPI 1730558834
Payments from drug & device makers
Across 548 payments — averaging $95.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$42K
- Neurocrine Biosciences, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Alkermes, Inc.$1K
- AbbVie$1K
- Indivior Inc.$591
- plus $3K from 29 others
What the payments were for
- Consulting fees$8,34016%
- Speaking & faculty fees$27,96054%
- Travel & lodging$4,3048%
- Food & beverage$10,98521%
- Education$6691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 148 | $42,240 |
| Neurocrine Biosciences, Inc. | 99 | $2,037 |
| E.r. Squibb & Sons, L.L.C. | 11 | $1,647 |
| Alkermes, Inc. | 52 | $1,182 |
| AbbVie | 48 | $1,179 |
| Indivior Inc. | 32 | $591 |
| USWM, LLC | 27 | $409 |
| Otsuka America Pharmaceutical, Inc. | 21 | $402 |
| AstraZeneca | 9 | $392 |
| Johnson & Johnson | 15 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $314 |
| Axsome Therapeutics, Inc. | 6 | $240 |
| Merck | 14 | $221 |
| Braeburn Inc. | 8 | $157 |
| Gilead | 5 | $116 |
| Boston Scientific | 3 | $114 |
| Astellas Pharma US Inc | 4 | $96 |
| Tempus AI, Inc | 4 | $83 |
| Sunovion Pharmaceuticals Inc. | 4 | $73 |
| Sage Therapeutics, LLC | 3 | $49 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Pfizer | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Myriad Women's Health, Inc. | 1 | $30 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Exeltis, USA Inc. | 1 | $17 |
| GSK | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,258 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $56,294 |
| ViberziEluxadoline | 12 | $18,542 |
| TrulicityDulaglutide | 11 | $13,021 |
| EliquisApixaban | 12 | $11,393 |
| BelsomraSuvorexant | 19 | $9,926 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $436 |
| Pregabalin | 18 | $328 |
| Duloxetine Hcl | 19 | $323 |
| Hydroxyzine Hcl | 14 | $313 |
| Baclofen | 12 | $214 |
| Chlorthalidone | 13 | $179 |
| Gabapentin | 11 | $178 |
| Bupropion XlBupropion Hcl | 14 | $150 |
| Metformin Hcl ErMetformin Hcl | 20 | $99 |
| Levothyroxine Sodium | 13 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $116 | $56,29413 claims |
| AbbVieViberzi | $1,179 | $18,54212 claims |
| Lilly USA, LLCTrulicity | $33 | $13,02111 claims |
| PfizerEliquis | $39 | $11,39312 claims |
| MerckBelsomra | $221 | $9,92619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Colorado Springs
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- Jeannette LillerColorado Springs$74K
- Stephanie HanenbergColorado Springs$40K
- Barbara ChamnessColorado Springs$15K
- Julie UnruhColorado Springs$14K
- Lisa HutchcraftColorado Springs$13K
- Kristin SekelskyColorado Springs$10K
- Leandrea TzitzicasColorado Springs$9K
- Lisa DudzikColorado Springs$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.